Isolation of a novel KIR2DL3-specific mAb: comparative analysis of the surface distribution and function of KIR2DL2, KIR2DL3 and KIR2DS2 by M. Vitale et al.
Isolation of a novel KIR2DL3-specific mAb:
comparative analysis of the surface distribution
and function of KIR2DL2, KIR2DL3 and KIR2DS2
Massimo Vitale1, Simona Carlomagno2, Michela Falco3, Daniela Pende1, Elisa Romeo3,
Paola Rivera2, Mariella Della Chiesa2, Domenico Mavilio4 and Alessandro Moretta2,5
1Istituto Nazionale per la Ricerca sul Cancro, L.go R. Benzi 10, 16132 Genova, Italy
2Dipartimento di Medicina Sperimentale, Universita` degli Studi di Genova, Via L.B. Alberti 2, 16132 Genova
3Istituto Giannina Gaslini, L.go G. Gaslini 5, 16148 Genova, Italy
4Laboratory of Immunoregulation, National Institute of Allergy and Infectious Disease, NIH, Bethesda, MD 20892, USA
5Centro di Eccellenza per le Ricerche Biomediche, Universita` degli Studi di Genova, V.le Benedetto XV, 16132 Genova, Italy
Keywords: HLA-specific receptors, immunoglobulin superfamily, KIR, NK cells
Abstract
In recent years an increasing number of sequences coding for new KIRs have been described.
However, the limited availability of mAbs with unique KIR specificities has hindered an exhaustive
assessment of their actual function, HLA-specificity, expression at the cell surface and distribution in
different cell populations. In this study we report the generation of a novel mAb (ECM41) specific for
KIR2DL3 molecules. By the use of cell transfectants expressing one or other KIR we show that this
reagent allows discrimination of KIR2DL3 from other GL183 mAb-reactive molecules such as KIR2DL2
and KIR2DS2. Moreover we show that this novel mAb can be used to assess the surface expression
and distribution of KIR2DL3 in different polyclonal NK populations and in NK cell clones. Along this
line, we were able to analyze the HLA class I specificity of NK clones expressing either KIR2DL3 or
KIR2DL2, two inhibitory receptors that were so far serologically undistinguishable. Finally, the
combined use of GL183 and ECM41 mAbs in redirected killing assays allowed us to investigate the
functional outcome of the simultaneous engagement of KIR2DL3 and KIR2DS2 in NK cell clones co-
expressing KIRs that display opposite (inhibitory vs activating) function.
Introduction
The NK cell effector function is finely modulated by a series of
different surface receptors able to transduce either positive or
negative signals (1). In humans, the activating receptors are
represented by an array of different receptors and co-
receptors including the Natural Cytotoxicity Receptors (NCR)
(i.e. NKp46, NKp30 and NKp44) (2), NKG2D (3–5), 2B4 (6–8),
NTB-A (9,10), NKp80 (11), CD59 (12) and DNAM 1 (13,14).
The main inhibitory receptors include the Killer Ig-like
Receptors (KIRs) (15–17), the CD94–NKG2A heterodimer
(18,19) and LIR 1/ILT2 (20–22). In particular, KIRs represent
a family of clonally distributed receptors, each specific for
a different group of HLA class I alleles (15). In their inhibitory
forms, KIRs are characterized by the presence of two or three
extracytoplasmic Ig-like domains (KIR2D or KIR3D) and trans-
duce the inhibitory signal through the phosphorylation of
Immuno Tyrosine-based Inhibitory Motifs (ITIM) inserted in
their long cytoplasmic tail (KIR2DL or KIR3DL) (15,17,23).
Through NCRs, NKG2D and the various co-receptors NK cells
can recognize and kill NK-susceptible target cells while
inhibitory KIRs, through their interaction with self HLA class I
molecules on target cells, prevent NK cells from killing normal
cells. Thus the expression of appropriate HLA-specific in-
hibitory receptors (i.e. specific for given self HLA class I allele)
on NK cells is a necessary requirement to avoid the indiscrim-
inate attack of normal tissues by NK cells. In this context, it
should be noted that in recent years an increasing number of
sequences coding for novel KIRs have been identified (24–26).
However, due to the frequent lack of mAbs with unique KIR
specificities, the actual surface expression, distribution and
HLA-specificityof thesemolecules remains incompletelysolved.
Interestingly, beyond the inhibitory KIRs, NK cells can also
express activating KIRs (15,27,28). These molecules are
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characterized by a short cytoplasmic tail (KIR2DS or KIR3DS)
that lacks inhibitory motifs and associates to KARAP/DAP12
polypeptides (29,30). Notably, KARAP contains ITAM that are
involved in the transduction of triggering signals. Some of the
activating KIRs display a high degree of homology with the
correspondent inhibitory KIR and at least in some cases have
also been shown to recognize (although with lower efficiency)
the same HLA class I alleles (25,31,32). Given the high degree
of homology between different KIRs, most of the KIR-specific
mAbs recognize epitopes shared not only by two or more
inhibitory KIRs but also by their activating counterpart. For
example no mAbs are available to discriminate KIR2DL1
(inhibitory) from KIR2DS1 (activating) (both reactive with the
EB6 or EB6-like mAbs) (15,33); or KIR2DL2 (inhibitory) from
KIR2DL3 (inhibitory) and from KIR2DS2 (activating) (all
reactive with the GL183 or GL183-like mAbs) (15,33).
To gain further information on the functional relationship
between activating and inhibitory KIRs, it would be useful to
obtain mAbs allowing to distinguish, for example, the inhibitory
form of a given KIR from its activating counterpart. This would
enable us to establish at the single cell level which ones
among the different KIRs recognized by a given mAb are
actually expressed. Importantly, such mAbs would also allow
the functional analysis of KIRs whose activating and inhibitory
forms might be co-expressed at the surface of the same NK
cell.
In this study we describe a novel mAb (termed ECM41)
able to discriminate the KIR2DL3 molecule from the other
two GL183 mAb reactive KIRs (KIR2DL2 and KIR2DS2). By
the combined use of ECM41 and GL183 mAbs, we were able
to analyze the expression, the distribution and the HLA-
specificity of two inhibitory receptors: KIR2DL3 and KIR2DL2,
that were so far serologically indistinguishable. We were also
able to analyze the functional cross-talk between KIR2DL3
and KIR2DS2 in NK cells co-expressing these two previously
indistinguishable GL183-reactive molecules.
Methods
Monoclonal antibodies
The following mAbs were produced in our lab: JT3A (IgG2a,
anti-CD3), BAB281 (IgG1, anti-NKp46), c127 (IgG1, anti-
CD16), c218 (IgG1, anti-CD56), A6/136 (IgM, anti-HLA class
I), EB6b (IgG1, anti-KIR2DL1/CD158a and KIR2DS1/
CD158h), GL183 (IgG1, anti-KIR2DL2/CD158b1, KIR2DL3/
CD158b2 and KIR2DS2/CD158j), DF200 (IgG1, anti-KIR2DL1,
KIR2DS1, KIR2DL2, KIR2DL3 and KIR2DS2), FES172 (IgG2a,
anti-KIR2DS4/CD158i), Z27 (IgG1, anti-KIR3DL1/CD158e1
and KIR3DS1/CD158e2), Q66 (IgM, anti-KIR3DL2/CD158k),
AZ158 (IgG2A, anti-KIR3DL1 and KIR3DL2) (15). D1.12
(IgG2a, anti-HLA-DR) mAb was provided by Dr R.S. Accolla
(Pavia, Italy). HP2.6 (IgG2a, anti-CD4) mAb was provided by
Dr P. Sanchez (Madrid, Spain).
Purification of peripheral blood lymphocytes (PBL) and
generation of polyclonal or clonal NK cell populations
Peripheral blood lymphocytes (PBL) were derived from
healthy donors by Ficoll–Hipaque gradients and depletion of
plastic-adherent cells. In order to obtain purified NK cells, PBL
were incubated with anti-CD3 (JT3A), anti-CD4 (HP2.6) and
anti-HLA-DR (D1.12) mAbs (30 min at 4C) followed by goat
anti-mouse coated Dynabeads (Dynal, Oslo, Norway) (30 min
at 4C) and immunomagnetic depletion (33). CD34DR
cells were cultured on irradiated feeder cells in the presence of
100 U/ml rIL-2 (Proleukin, Chiron Corp., Emeryville, USA) and
1.5 ng/ml PHA (Gibco Ltd, Paisley, Scotland) in order to obtain
polyclonal NK cell populations or, after limiting dilution, NK cell
clones.
Flow cytofluorimetric analysis
Cells were stained with the appropriate mAb followed by PE-
or FITC-conjugated isotype-specific goat anti-mouse second
reagent (Southern Biotechnology Associated, Birmingham,
AL). Samples were analyzed by one- or two-color cytofluori-
metric analysis (FACSCalibur Becton Dickinson & Co.,
Mountain View, CA) as previously described (33).
Transient tranfections
HEK-293Tcells (43 105/plate) were transfected with plasmids
coding for the following molecules: KIR2DL1, KIR2DL2,
KIR2DL3, KIR2DS1, KIR2DS2, KIR2DS4, KIR3DL1 and
KIR3DL2 using FuGene-6 reagent. After 48 h, transfected
cells were stained with ECM41, GL183, EB6b, DF200, FES172,
Z27, Q66 and AZ158 mAbs followed by isotype-specific PE-
conjugated goat anti-mouse second reagent and analyzed by
flow cytometry using a FACSort (Becton Dickinson).
Amplification and sequencing of KIR transcripts
Total RNA samples were extracted using peqGOLD RNAPure
(Erlangen, Germany) and oligo (dT)-primed cDNA were
prepared by standard techniques. The coding primer Ig3-up
59-CATgTYgCTCAYggTCgTC was used in combination with
the reverse primer E: 59-gTTCCgYgTACACgATgA or C: 59-
AAAACACAgTgATCCAATTA to amplify inhibitory or activating
KIR transcripts respectively (30 sec at 95C, 30 sec at 60C
and 30 sec at 72C). All the amplification products were
purified from gel, and subcloned into pcDNA3.1/V5/His-TOPO
vector using the Eukaryotic-TOPO-TA cloning kit (Invitrogen,
Carlsbad, CA). To identify the KIR2D expressed in the
analyzed samples, at least 15 independent clones were
sequenced using d-Rhodamine Terminator Cycle Sequencing
kit and a 377 ABI automatic sequencer (Perkin Elmer-Applied
Biosystems).
Cytolytic assays
NK cells were tested for cytolytic activity in a 4 h 51Cr-release
assay either in the absence or presence of the indicated
mAbs. The FccR+ P815 (murine mastocytoma) target cell line
was used for redirected killing experiments. Other target cells
used in these studies were represented by the following B-LCL
human cell lines: HLA-class I 721.221 cell line either
untransfected or transfected with various classical HLA-class
I alleles; EBV-24 (obtained in our lab) and KOSE (a kind gift
from G.B. Ferrara, Genova, Italy).
The concentrations of the various mAbs were 10 lg/ml for
the masking experiments and 0.5 lg/ml for the redirected
killing experiments. The E/T ratios are indicated in the text.
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Results
ECM41 mAb specifically recognizes KIR2DL3
Mice were immunized with a polyclonal human NK cell line
derived from a healthy individual (donor 1) and after fusion, the
hybridoma supernatants were first selected by cytofluorimetric
analysis on the basis of their ability to stain NK cell
subpopulations within the immunizing NK cell line. The
reactivity of the selected mAbs was then compared by single
and double fluorescence to that of various KIR-specific mAbs
including: EB6b (anti-KIR2DL1 and KIR2DS1), GL183 (anti-
KIR2DL2, KIR2DL3 and KIR2DS2), FES172 (anti-KIR2DS4),
Z27 (anti-KIR3DL1), Q66 (anti-KIR3DL2). By this approach we
could identify a mAb, termed ECM41 (IgM) that displayed
a specificity similar to that of the GL183 mAb. Indeed, as
shown in Fig. 1 (donor 1), double fluorescence cytofluorimetric
analysis indicated that the two mAbs marked precisely the
same NK cell subset and that all double fluorescent cells were
distributed along a diagonal, thus suggesting that the two
mAbs were directed to the same surface molecule. However,
the analysis of NK cells derived from a large panel of donors
revealed that only in ~30% of the cases did the reactivity of the
two mAbs overlap as in donor 1. Indeed, in the remaining 60%
of the cases, ECM41 mAb stained only a fraction of the
GL183+ cells (Fig. 1, donor 2), while in rare cases (10%)
ECM41 mAb did not react with the GL183+ cell population
analyzed (Fig. 1, donor 3). Importantly, in no instances was
ECM41 mAb found to react with GL183 NK cells. Further-
more, the reactivity of ECM41mAb did not correlate with any of
the other KIR-specific mAbs mentioned above. Therefore the
ECM41 mAb appeared to selectively stain a subset of the
GL183+ NK cells, thus suggesting a possible reactivity with
only one (or two) of the molecules recognized by the GL183
mAb.
To address this possibility we analyzed the reactivity of
ECM41 mAb on HEK-293T cells transiently transfected with
plasmids coding for KIR2DL2, KIR2DL3 or KIR2DS2 (i.e. KIRs
stained by conventional GL183 mAb). As shown in Fig. 2,
ECM41 mAb selectively stained KIR2DL3+-transfected cells
while, as expected, the GL183 mAb brightly stained all three
cell transfectants. The analysis was then extended to HEK-
293T cells transfected with one or other of the remaining KIRs
whose surface expression could be detected by available
specific mAbs. These included KIR2DL1, KIR2DS1, KIR2DS4,
Fig. 1. Cytofluorimetric analysis of ECM41 and GL183-reactive molecules on polyclonal NK cells. Polyclonal NK cell lines derived from
representative donors were stained with the indicated mAbs followed by FITC- or PE-conjugated isotype-specific goat anti-mouse second
reagents. Similar results were obtained by the analysis of freshly isolated NK cells from the same donors. These results are representative of more
than 20 donors analyzed.
Fig. 2. ECM41 mAb specifically recognizes KIR2DL3 molecule. HEK-293Tcells transiently transfected with the indicated constructs were stained
with GL183 or ECM41 mAbs followed by PE-conjugated goat anti-mouse isotype specific second reagents. Gray profiles indicate staining with
second reagent alone. Cells were analyzed by cytofluorimetry.
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KIR3DL1 and KIR3DL2. As summarized in Table 1, none of
these transfectants was stained by ECM41 mAb.
These results demonstrate that ECM41 mAb represents
a unique reagent able to discriminate KIR2DL3 from other
KIRs, and in particular from other GL183 mAb-reactive KIRs
(KIR2DL2 and KIR2DS2). Based on this finding, the profiles
shown in Fig. 1 would be representative of the distribution of
distinct GL183-reactive KIRs in NK cells derived from different
donors. In particular, the GL183+ECM41+ cells (observed in
donors 1 and 2) correspond to those expressing KIR2DL3
while GL183+ECM41 cells (observed in donors 2 and 3)
represent those expressing KIR2DL2 and/or KIR2DS2 but not
KIR2DL3.
KIR2DL2 and KIR2DL3 recognize the same HLA-C alleles
By the use of soluble KIR molecules, KIR2DL2 and KIR2DL3
have been shown to react with a defined cluster of HLA-C
alleles identified by the presence of the Asn80 residue (HLA-
CAsn80 alleles) (25,31,34,35). Here we analyzed the HLA
specificity of single NK clones expressing one or other of the
two distinct GL183 mAb-reactive inhibitory KIRs. To this end
we selected NK cell clones characterized by the
GL183+ECM41+ and the GL183+ECM41 phenotypes and
analyzed their KIR transcripts. The sequences of the RT–PCR
products obtained using primer pairs able to amplify the
inhibitory KIR revealed that some of GL183+ECM41+ clones
were KIR2DL3+KIR2DL2, while others were
KIR2DL3+KIR2DL2+ (not shown). Two NK clones were further
selected on the basis of their phenotypes and utilized in
functional analysis. Clone DP1 expressed the GL183+ECM41+
(KIR2DL3+KIR2DL2) phenotype while clone L38 expressed
the GL183+ECM41 (KIR2DL3KIR2DL2+) phenotype. Both
the clones were NKG2A and did not react with other available
KIR-specific mAbs. DP1 and L38 were analyzed for cytolytic
activity against a panel of B EBV-transformed target cells
expressing HLA-CAsn80 alleles. These targets included: the
HLA class I negative 221 cell line transfected with HLA-Cw3 or
-Cw8 alleles and the homozygous cell lines EBV24 and EBV-
KOSE expressing the HLA-Cw7 and -Cw12 alleles, respect-
ively. As shown in Fig. 3, both NK clones efficiently killed
untransfected 221 cells while sparing all the other target cells.
However, the HLA-C positive targets were lysed by both
Table 1. Specificity of different anti-KIR mAb
KIR-specific mAbs KIR2DL3 KIR2DL2 KIR2DS2 KIR2DL1 KIR2DS1 KIR2DS4 KIR3DL1 KIR3DL2
ECM 41 +       
GL 183 + + +     
EB6b    + +   
DF 200 + + + + +   
FES 172      +  
Z27       + 
Q66        +
AZ 158       + +
The mAbs shown in the first column were analyzed for their ability to stain the HEK-293T cell line transfected with one or another of the indi-
cated KIR.
Fig. 3. KIR2DL2+ and KIR2DL3+ NK clones recognize the HLA-CAsn80 alleles. The following NK cell clones, DP1 (KIR2DL2KIR2DL3+), L38
(KIR2DL2+KIR2DL3) and DP5 (KIR2DL2KIR2DL3), were analyzed in a cytolytic assay against the HLA class I negative (221) or HLA-CAsn80
positive (221-Cw3, 221-Cw8, EBV24 and KOSE) targets. The reactivity with GL183 and ECM41mAb (in brackets) for each clone is also shown. The
experiments (representative of five independent tests) were carried out either in the absence (CTR) or in the presence of the indicated mAbs
(anti-HLA class I mAb is represented by the A6/136 mAb). E/T ratio: 3/1.
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clones in the presence of appropriate anti-HLA class I specific
mAb. These data indicate that both KIR2DL3 (expressed by
DP1) and KIR2DL2 (expressed by L38) were able to recognize
HLA-Cw3, -w7, -w8 and -w12 alleles. This was further
confirmed by the fact that mAb-mediated masking of either
KIR2DL2 (by addition of GL183 mAb on clone L38) or
KIR2DL3 (by addition of either ECM41 or GL183 mAb on
clone DP1) efficiently reconstituted lysis of the above HLA-C-
protected target cells. These results are representative of >20
clones analyzed. In these experiments, control NK clones
lacking KIR2DL2/3 such as clone DP5 (NKG2AKIR2DL2/
3KIR2DS2KIR2DL1+) displayed cytolytic activity against
both transfected and untransfected 221 cells, as well as
against the two homozygous cell lines.
Although not shown, both GL183+ NK clones (L38 and DP1)
efficiently killed 221 cells transfected with HLA class I alleles
different from those belonging to the HLA-CAsn80 group, thus
confirming that both KIR2DL2 and KIR2DL3 confer the same
HLA specificity to NK cells.
Analysis of NK clones co-expressing the inhibitory and the
activating forms of GL183 mAb reactive molecules
As mentioned above, available KIR2D-specific mAbs cannot
discriminate between the activating and the inhibitory form of
a given KIR. Indeed, to determine the precise type of KIR
expressed at the surface of a given NK cell clone, beyond the
cytofluorimetric analysis, a direct functional analysis is
generally required. Thus KIR-specific mAb (of the IgG
isotype) can be assessed in redirected killing assay for their
ability to modulate the spontaneous NK-mediated killing of
FccR+ P815 murine target cells. In this type of assay, mAbs
directed to triggering receptors induce increments of cytotox-
icity whereas mAbs to inhibitory receptors reduce the
spontaneous NK-mediated lysis of P815. The use of a mAb
specific for both the activating and the inhibitory form of
a given receptor (such as the GL183 mAb) does not
allow a precise assessment of the functional nature of the
KIR recognized, especially when these molecules are co-
expressed at the cell surface. Indeed, in this case, since in NK
cells the inhibitory signals generally suppress the activating
ones, the simultaneous engagement of the two receptors
might be expected to result in inhibition of cytotoxicity. The
availability of the ECM41 mAb, however, may offer the
possibility of overcoming this problem. Indeed in a ‘redirected
killing assay’ the use of ECM41 mAb, which is of the IgM
isotype and therefore unable to bind to Fc-receptors ex-
pressed on P815, would provide a selective masking of
KIR2DL3 without induction of negative signals. In the case of
clones co-expressing KIR2DL3 and KIR2DS2, the ECM41
mAb would then compete with GL183 mAb for binding to
KIR2DL3 and, as a result of this competition, the GL183 mAb
would prevalently react with KIR2DS2. The effect of the GL183
mAb alone or in combination with the ECM41 mAb was then
analyzed in a redirected killing assay on a panel of>50 NK cell
clones expressing the GL183+ECM41+ phenotype. As ex-
pected, the NK-mediated lysis of most of these clones was
inhibited by the GL183 mAb used alone. Importantly, this
inhibition was weakened (but not reverted) when GL183 was
used in combination with the ECM41 mAb (see the represen-
tative clone P8/2 in Fig. 4A). In a few NK clones however (that
were named ‘ECM41/Act’ NK clones), the addition of ECM41
mAb completely abrogated the inhibitory effect of the GL183
mAb, resulting in strong increase of cytotoxicity (see the
representative clone P8/6 in Fig. 4A and five additional clones
in Fig. 4B). In these clones, the triggering effect induced by the
combination of ECM41 and GL183 mAbs was comparable in
magnitude to that induced by GL183 mAb alone on a clone
expressing KIR2DS2 but not KIR2DL2/3 (clone P19/100,
Fig. 4A). The effects mediated by ECM41 mAb were specific,
since (i) they could not be obtained by other mAbs of the IgM
isotype (including the A6/220mAb, specific for the CD56mole-
cule, and the Y249mAb that displays the same reactivity of the
GL183 mAb) (data not shown); and (ii) when added alone,
ECM41 mAb didn’t affect the spontaneous NK-mediated
killing of P815 target cells (Fig. 4A).
Thus, while the results obtained on clone P8/2 can be
explained by the competition of ECM41 and GL183 mAb
for KIR2DL3, the case of clone P8/6 suggested that both
KIR2DL3 and KIR2DS2 might have been expressed at the
cell surface. This was confirmed by molecular analysis of
the KIR transcripts present in clones P8/2, P8/6 and P19/100.
Indeed RT–PCR analysis revealed that the P8/2 clone
was KIR2DL2KIR2DL3+KIR2DS2, the P8/6 clone was
KIR2DL2KIR2DL3+KIR2DS2+ while the P19/100 clone was
KIR2DL2KIR2DL3KIR2DS2+.
In the ‘ECM41/Act’ NK clones (that should express the
KIR2DL2KIR2DL3+KIR2DS2+ phenotype) the inhibitory ef-
fect of GL183 mAb alone was variable, ranging from
a complete to a hardly detectable inhibition of the spontan-
eous NK-mediated lysis (Fig. 4B). This is explained by the fact
that in each clone the cytolytic outcome resulting from the
engagement of GL183-reactive KIRs depends on the balance
between the signals delivered by inhibitory vs activating KIRs.
The mAb-mediated engagement of KIR2DL3 resulted in
strong inhibition of NK cell activation induced simultaneously
via different triggering NK receptors. Indeed, as shown in
clone P8/6 (Fig. 4A), the simultaneous addition of GL183 mAb
(that in this clone interacts with both KIR2DL3 and KIR2DS2)
and of anti-NKp46 mAb resulted in inhibitory signals capable
of abrogating lysis.
Discussion
In this study, by the generation of a novel KIR-specific mAb
(ECM41), we could compare the cell surface distribution and
HLA specificity of two inhibitory KIRs (KIR2DL2 and KIR2DL3)
that were previously identified but not distinguished by the
GL183 mAb. Remarkably, this novel reagent, which is specific
for KIR2DL3, also allows the functional dissection of GL183-
reactive activating and inhibitory receptors co-expressed at
the cell surface of given NK cells.
Previous studies indicated that the HLA-C alleles bearing
residues Ser77–Asn80 (initially identified as ‘group 1’ alleles)
are recognized by inhibitory KIRs identified by the GL183 mAb
(15,33,36–38). These receptors, that were originally termed
p58.2, consist of two distinct gene products termed KIR2DL2
and KIR2DL3. Their HLA specificity was previously assessed
through the combined use of either soluble KIR molecules or
GL183+ NK clones and HLA class I transfected cell lines.
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However, the functional experiments aimed to compare
KIR2DL2+ and KIR2DL3+ NK clones were impaired by the
lack of mAbs able to discriminate between the two different
KIRs. The novel ECM41 mAb specifically recognizes KIR2DL3
but not KIR2DL2, and therefore allows the identification of
GL183+ KIR2DL3+ and GL183+KIR2DL3 NK clones. The
analysis of the two types of NK clones confirmed that indeed
both KIR2DL2 and KIR2DL3 recognize essentially the same
pattern of HLA class I alleles. This result is nevertheless
important, since the assessment of the precise HLA specificity
of a given KIR may represent a crucial requirement in case the
NK cells should be employed in hematopoietic transplants as
proposed by Ruggeri et al. (39,40).
In this study, we also evaluated the effect of the simultan-
eous engagement of activating and inhibitory KIRs reacting
with GL183 mAb. Our results clearly indicate the occurrence
of NK clones expressing both KIR2DS and KIR2DL at the
cell surface. In these clones, the effect mediated by the
inhibitory KIR overrides that of the activating one. Indeed, in
clones expressing the KIR2DS2+KIR2DL3+ phenotype, the
GL183 mAb-dependent KIR2DS2 cross-linking resulted in an
enhancement of cytolytic activity only after masking of the
inhibitory KIR2DL3 by the ECM41 mAb. A recent study by
Warren et al. suggested that KIR2DS2 and KIR2DL2/3, also
when co-expressed, may exert their function independently
(41). However, the above experiments were carried out using
Fig. 4. The combined use of ECM41 and GL183 mAbs in a redirected killing assay allows the identification of KIR2DL3+KIR2DS2+ and
KIR2DL3+KIR2DS2 NK clones. (A) The cytolytic activity against P815 target cells of three representative NK clones displaying the indicated KIR
phenotype (assessed by RT–PCR analysis) is shown. The reactivity with GL183 and ECM41 mAb (in brackets) for each clone is also indicated.
These two mAb were added alone or in combination (black bars) in the cytolytic test. GL183 mAb was also added in combination with anti-NKp46
mAb (BAB281) in order to assess the ability of KIR2DL3 to block simultaneously two different triggering signals (induced by KIR2DS2 and NKp46).
(B) The effect of GL183 and ECM41mAbwas analyzed on the cytolytic activity mediated by different KIR2DL3+KIR2DS2+ NK clones. Striped bars:
spontaneous lysis. Gray bars: lysis in the presence of GL183 mAb. Black bars: lysis in the presence of GL183 mAb + ECM41 mAb. All the
experiments were performed at an E:T ratio of 3:1. These results are representative of five independent experiments.
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mAbs unable to discriminate the two KIR types (for example
GL183) and therefore were unable to define the precise KIR
phenotype of the NK cell population under study.
Our analysis of a large panel of KIR2DS2+KIR2DL3+ NK
clones also revealed a certain variability in the activity of the
two KIR types. Indeed, depending on the clones analyzed, the
effect resulting from the simultaneous engagement of both
receptors by the GL183 mAb ranged between a strong to
a hardly detectable inhibition of the spontaneous NK-
mediated lysis of P815 target cells (Fig. 4B). This suggests
that the behavior of a given NK cell expressing both KIR2DS
and KIR2DL during the interaction with a cell target may result
(at least in part) from the balance of the signals delivered by
the two KIRs displaying opposite functions. Although both the
inhibitory and the activating KIRs are referred to as recogniz-
ing HLA class I molecules, important differences exist. For
example, the activating KIRs, different from the inhibitory ones,
appear to recognize HLA class I molecules with low efficiency.
We do not actually know whether the presence of abnormal
(viral?) peptides might strengthen the KIR2DS/HLA class I
interaction or whether virus-encoded HLA homologues would
represent the actual targets for the activating KIRs. Recent
reports suggest an involvement of the MHC-specific activating
NK receptors in the control of viral infections (42,43). In this
context, the co-expression of both inhibitory and activating
forms of a given KIR and their functional interactions may be
seen as a mechanism to ‘sense’ a differential loading of
abnormal vs normal peptides on a given HLA class I allele or
a differential expression of ‘homologous’ vs autologous HLA
class I molecules.
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B-LCL B-lymphoblastoid cell line
FccR Fcc-receptor
KARAP killer cell-activating receptors-associated polypeptides
KIR killer Ig-like receptors
NK natural killer
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